Scholars Central

ArticlePublished 27 Feb 2026

To evaluate real-world prescribing patterns, perceived effectiveness, safety, and combination practices of tofacitinib among Indian dermatologists

Authors: Manjunath Shenoy, Prakash C Bora, Shreya Poddar, Nisha Agrawal, T.N. Rekha Singh, Vijay S Joshi, Willem J Verberk, Shubhajit Paul

Journal of Dermatology and Dermatologic Diseases

Volume 13 · Issue 1 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Autoimmune skin diseases such as vitiligo, psoriasis, alopecia areata and atopic dermatitis cause substantial physical and psychosocial morbidity and durable remission remain challenging. The Janus kinase (JAK) pathway has emerged as a key therapeutic target, with tofacitinib-a JAK1/3 inhibitor offering a mechanism distinct from traditional immunosuppressant’s. Aims: To evaluate real-world prescribing patterns, perceived effectiveness, safety and combination practices of tofacitinib among Indian dermatologists. Methods: A cross-sectional, web-based survey (August-September 2024) of 825 Indian dermatologists used a validated 27-item questionnaire to assess prescribing trends, dosing, response timelines, adverse effects and management approaches. Results: Tofacitinib was most commonly prescribed for vitiligo and alopecia areata (97%), followed by psoriasis (93%) and atopic dermatitis (89%). Dermatologists predominantly treated individuals aged 12-40 years, using oral formulations alone or combined with topical corticosteroids (86%) or calcineurin inhibitors (71%). The usual starting regimen was 5 mg BID for 8 weeks, with follow-up every 4 weeks. Clinical improvement generally appeared within 4-8 weeks. Side effects included mild laboratory abnormalities (56%), gastrointestinal symptoms (47%) and cutaneous infections (33%), usually managed by dose adjustment. Over 90% of respondents rated tofacitinib effective for inducing remission and maintaining long-term control. Major concerns included limited Indian data (80%) and absence of national guidelines (66%). Conclusion: Tofacitinib shows growing acceptance in Indian dermatology, particularly for vitiligo and alopecia areata, with consistent improvement within 4-8 weeks. Dermatologists emphasized the need for more Indian-specific evidence and updated national guidelines to support its rational, wider use.

Subjects

Dermatology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Dermatology and Dermatologic Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Dermatology and Dermatologic Diseases
  • SubjectDermatology
  • BylineArticles whose byline prints “Manjunath Shenoy”
  • BylineArticles whose byline prints “Prakash C Bora”
  • BylineArticles whose byline prints “Shreya Poddar”
  • BylineArticles whose byline prints “Nisha Agrawal”
  • BylineArticles whose byline prints “T.N. Rekha Singh”
  • BylineArticles whose byline prints “Vijay S Joshi”
  • BylineArticles whose byline prints “Willem J Verberk”
  • BylineArticles whose byline prints “Shubhajit Paul”